Strata Critical Medical, Inc. SRTA
5.33
0.06
1.14%
as of 25 Sep
- Market cap
- $476.8M
- P/E
- 10.5×
Follow SRTA
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
10.39 | 7.24 | 9.49 | 10.33 |
+8 more quarters Free account |
P/S ratio |
1.78 | 1.56 | 2.00 | 3.43 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
79.89 | 91.80 | (47.53) | (11.19) | |
P/B ratio |
1.63 | 1.25 | 1.41 | 1.47 | |
Price to Tangible BV |
4.04 | 2.36 | 2.75 | 2.81 | |
EV/Sales |
1.69 | 1.30 | 1.69 | 2.80 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.97) | (6.65) | (6.82) | (8.05) | |
EV/FCF |
(8.71) | (5.12) | (5.56) | (6.05) | |
Quick Ratio |
1.45 | 4.71 | 5.13 | 4.08 | |
Current Ratio |
2.64 | 5.93 | 6.38 | 4.39 | |
Net Debt/EBITDA |
(7.41) | (686.66) | 18.10 | 19.44 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.87 | 0.79 | 0.68 | 0.39 | |
Operating CF/Net income |
(0.54) | 1.80 | 0.94 | (0.65) | |
Capex/Depreciation |
(0.33) | (1.79) | (0.67) | (1.87) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.92% | |
Selling, General and Administrative Expense of Revenue |
19.30% | 23.16% | 27.66% | 34.04% | |
Intangible Assets out of Total Assets |
0.50 | 0.41 | 0.42 | 0.40 | |
Share Based Compensation of Revenue |
5.11% | 7.47% | 9.86% | 3.41% | |
Graham Net Nets |
0.15 | 0.23 | 0.20 | 0.17 | |
Graham Number |
6.08 | 6.59 | 6.23 | 6.15 | |
Earnings Yield |
9.62% | 13.81% | 10.54% | 9.68% | |
Free Cash Flow Yield |
(10.90%) | (16.30%) | (15.18%) | (13.52%) | |
Revenue per Share |
0.84 | 0.79 | 0.81 | 0.60 | |
Operating CF per Share |
0.07 | 0.05 | (0.10) | (0.45) | |
Capex per Share |
(0.03) | (0.06) | (0.02) | (0.04) | |
Free Cash Flow per Share |
0.03 | (0.02) | (0.13) | (0.49) | |
Cash per Share |
0.27 | 0.69 | 0.75 | 0.92 | |
Shareholders Equity per Share |
3.24 | 3.35 | 3.40 | 3.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.24 | 3.35 | 3.40 | 3.43 | |
Free Cash Flow |
2.88 | (1.60) | (10.31) | (40.49) | |
Working Capital |
75.23 | 103.20 | 106.40 | 94.61 | |
Capital Expenditures |
(2.80) | (5.48) | (2.00) | (3.19) | |
Net Current Asset Value |
67.63 | 82.26 | 79.79 | 70.40 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.08 | 0.03 | 0.06 | |
Net Profit Margin |
(14.50%) | 3.20% | (13.23%) | 116.47% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
35.79 | 30.87 | 29.89 | 31.01 | |
Average Payables |
16.03 | 15.23 | 14.18 | 21.62 | |
Average Assets |
295.31 | 289.08 | 291.07 | 309.01 | |
Average Common Equity |
251.21 | 252.73 | 250.51 | 258.25 |
Columns are period end dates